Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α

2007 ◽  
Vol 102 (12) ◽  
pp. 2724-2731 ◽  
Author(s):  
Ursula Plöckinger ◽  
Denny Krüger ◽  
Alexandra Bergk ◽  
Viola Weich ◽  
Bertram Wiedenmann ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Term Therapy ◽  
Interferon Α ◽  
Gh Secretion ◽  
Long Term Therapy

Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients

1993 ◽  
Vol 129 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Yi-Fan Shi ◽  
Xian-Feng Zhu ◽  
Alan G Harris ◽  
Jin-Xi Zhang ◽  
Jie-Ying Deng
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Term Therapy ◽  
Serum Growth Hormone ◽  
Factor I ◽  
Gallbladder Contractility ◽  
Octreotide Therapy ◽  
Long Term Therapy ◽  
Growth Hormone Suppression

We sought to examine how the discontinuation of octreotide in long-term octreotide-treated acromegalic patients affects the well-documented side-effect of cholelithiasis. In 14 acromegalic patients, serum growth hormone levels, insulin-like growth factor I levels and percentage of relative gallbladder contractility were measured prior to and after the discontinuation of octreotide. Compared to pretreatment values, the basal growth hormone and 5-h growth hormone profiles were 36% and 24%, and 60% and 56% at the end of 1 and 2 weeks, respectively. Octreotide was found to be eliminated completely from the serum within 3 days after its withdrawal. In all of six patients who did not develop gallstones, the percentage relative gallbladder contractility normalized within 1 week. In eight patients who developed gallstones, four of them had restoration of normal contractility within 2 weeks. Our results show that upon withdrawal of octreotide, gallbladder contractility returns to normal while growth hormone suppression persists for a longer period of time. Therefore, discontinuation of octreotide therapy may allow for the clearance of stagnated bile and hence decrease the incidence of cholelithiasis in acromegalic patients receiving long-term therapy.

Good response to long-term therapy with growth hormone in a patient with 9p trisomy syndrome: A case report and review of the literature

2015 ◽  
Vol 170 (4) ◽  
pp. 1046-1049 ◽  
Author(s):  
Ana Pinheiro Machado Canton ◽  
Mirian Yumie Nishi ◽  
Tatiane Katsue Furuya ◽  
Rosimeire Aparecida Roela ◽  
Alexander Augusto Lima Jorge
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Term Therapy ◽  
Review Of The Literature ◽  
Long Term Therapy

scholarly journals Effects of Growth Hormone on Craniofacial Growth

2006 ◽  
Vol 76 (6) ◽  
pp. 970-977 ◽  
Author(s):  
Minayo Funatsu ◽  
Koshi Sato ◽  
Hideo Mitani
Keyword(s):  
Growth Hormone ◽  
Therapy Group ◽  
Untreated Group ◽  
Term Therapy ◽  
Craniofacial Growth ◽  
Gh Therapy ◽  
Facial Height ◽  
Long Term Therapy ◽  
Ramus Height

Abstract Objective: This study determined the effects of growth hormone (GH) therapy on craniofacial growth in idiopathic growth hormone deficiency (GHD). Materials and Methods: Fifty-seven patients (33 boys and 24 girls; age range 4.5 to 16.7 years) with GHD were investigated and categorized into three groups according to the duration of GH therapy: the untreated group, the short-term therapy group, and the long-term therapy group. Their lateral cephalometric radiographs were studied, and craniofacial measurements were assessed by age and sex by using matched standard deviation scores. Results: In the untreated group, the anterior cranial base, total facial height, maxillary length, mandibular total length, mandibular body length, and ramus height were smaller than the standard values. In comparison with the untreated group, the long-term therapy group had a significantly larger upper facial height (P < .05), maxillary length (P < .01), and ramus height (P < .01) measurements. Conclusions: Children who received long-term GH replacement therapy showed increased growth of the craniofacial skeleton, especially the maxilla and ramus. These findings suggest that GH accelerates craniofacial development, which improves occlusion and the facial profile.

Sign in / Sign up

Export Citation Format

Share Document